Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ...
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...
The World Health Organization says chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death ...
Chronic obstructive pulmonary disease (COPD) affects approximately 29 million people in the U.S. and is the fourth leading ...
Veterans of the U.S. military face unique respiratory risks, but physicians can guide them through care with the aid of the Department of Veterans Affairs, according to a presentation at the CHEST ...
RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, ...
Savara Inc. (NASDAQ:SVRA) is one of the top long-term biotechnology stocks to buy. On October 2, Savara Inc. (NASDAQ:SVRA) ...
A significant link was found between active cigarette smoking and an elevated rate of pneumonia in COPD, whereas this was not ...
Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...
Dr. Gladwin received his medical degree from the University of Miami in 1991. He completed residency at the Oregon Health Sciences University in Portland, followed by a Critical Care fellowship at the ...
May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback